Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edmond Teng

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Neurobiology of Disease|March 5, 2018
Neuronal pentraxin 1: A synaptic-derived plasma biomarker in Alzheimer's diseaseQiu-Lan Ma, Edmond Teng, Xiaohong Zuo, et al.
Neurology|August 29, 2023
Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: LaurietCecilia Monteiro, Balazs Toth, Flavia Brunstein, et al.
JAMA Neurology|June 13, 2022
Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical TrialEdmond Teng, Paul T Manser, Karen Pickthorn, et al.
Neurology. Genetics|April 12, 2016
Alzheimer risk genes modulate the relationship between plasma apoE and cortical PiB bindingAndreas Lazaris, Kristy S Hwang, Naira Goukasian, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|June 3, 2008
Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteriaEdmond Teng, John M Ringman, Leslie K Ross, et al.
Neurobiology of Disease|May 25, 2011
[F-18]FDDNP microPET imaging correlates with brain Aβ burden in a transgenic rat model of Alzheimer disease: effects of aging, in vivo blockade, and anti-Aβ antibody treatmentEdmond Teng, Vladimir Kepe, Sally A Frautschy, et al.
Alzheimer'S Research & Therapy|May 6, 2017
Communicating mild cognitive impairment diagnoses with and without amyloid imagingJoshua D Grill, Liana G Apostolova, Szofia Bullain, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 8, 2024
Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiologyStephen P Schauer, Balazs Toth, Julie Lee, et al.
Alzheimer'S Research & Therapy|October 31, 2012
Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled studyJohn M Ringman, Sally A Frautschy, Edmond Teng, et al.
Neurology|December 13, 2024
Phase 2A Proof-of-Concept Double-Blind, Randomized, Placebo-Controlled Trial of Nicotinamide in Early Alzheimer DiseaseJoshua D Grill, Steven Tam, Gaby Thai, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Neurobiology of Disease|March 5, 2018
Neuronal pentraxin 1: A synaptic-derived plasma biomarker in Alzheimer's diseaseQiu-Lan Ma, Edmond Teng, Xiaohong Zuo, et al.
Neurology|August 29, 2023
Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: LaurietCecilia Monteiro, Balazs Toth, Flavia Brunstein, et al.
JAMA Neurology|June 13, 2022
Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical TrialEdmond Teng, Paul T Manser, Karen Pickthorn, et al.
Neurology. Genetics|April 12, 2016
Alzheimer risk genes modulate the relationship between plasma apoE and cortical PiB bindingAndreas Lazaris, Kristy S Hwang, Naira Goukasian, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|June 3, 2008
Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteriaEdmond Teng, John M Ringman, Leslie K Ross, et al.
Neurobiology of Disease|May 25, 2011
[F-18]FDDNP microPET imaging correlates with brain Aβ burden in a transgenic rat model of Alzheimer disease: effects of aging, in vivo blockade, and anti-Aβ antibody treatmentEdmond Teng, Vladimir Kepe, Sally A Frautschy, et al.
Alzheimer'S Research & Therapy|May 6, 2017
Communicating mild cognitive impairment diagnoses with and without amyloid imagingJoshua D Grill, Liana G Apostolova, Szofia Bullain, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 8, 2024
Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiologyStephen P Schauer, Balazs Toth, Julie Lee, et al.
Alzheimer'S Research & Therapy|October 31, 2012
Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled studyJohn M Ringman, Sally A Frautschy, Edmond Teng, et al.
Neurology|December 13, 2024
Phase 2A Proof-of-Concept Double-Blind, Randomized, Placebo-Controlled Trial of Nicotinamide in Early Alzheimer DiseaseJoshua D Grill, Steven Tam, Gaby Thai, et al.
Pageof 8